Screener
BioCryst Pharmaceuticals BCRX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's total liabilities?
- BioCryst Pharmaceuticals (BCRX) reported total liabilities of $1.01B in Q2 2026.
- How has BioCryst Pharmaceuticals's total liabilities changed year-over-year?
- BioCryst Pharmaceuticals's total liabilities increased by 15.2% year-over-year, from $878.78M to $1.01B.
- What is the long-term trend for BioCryst Pharmaceuticals's total liabilities?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's total liabilities has grown at a -19.3% compound annual growth rate (CAGR), from $972.49M to $633.31M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about BioCryst Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude